ArticleScientific reports2025
Structure-based design of an antibacterial peptide from the Myotoxin II sequence, evaluating its effectiveness against Gram-negative bacteria and its safety.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computer-Aided Drug Design, Synthesis, and In Vitro Safety Evaluation of Carprofen Analogs for Novel Alzheimer's Disease Therapeutics.ChemMedChem · 2026Article
- Brief history of ophidiology and ophidism in Colombia.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Review
- Artificial neural network as a strategy to predict rheological properties in emulgel formulations.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial resistance poses a significant public health challenge, particularly for pathogens prioritized by the World Health Organization, such as carbapenem-resistant Escherichia coli. There has been growing interest in exploring animal toxins as potential alternatives to antibiotics. This study centers on the rational design of an antibiotic peptide based on the sequence 115-129 from Myotoxin II, sourced from the venom of the snake Bothrops asper. We modified the original sequence 20 times using molecular docking and found that peptide sequence 20 (KHWYKHYRH) exhibited the highest affinity energy of - 7.6 kcal/mol for lipopolysaccharide (LPS). The in vitro potency was assessed against E. coli, with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.